 Home > Medical News > Medicines Company News > Heqirui Medicine completes US$56 million in Series B financing

Heqirui Medicine completes US$56 million in Series B financing

 Last Update: 2021-07-07
 Source: Internet
 Author: User

Tags

pcp drug class

clinical development

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Hope Medicine Inc.
(Heqirui Medicine) announced the completion of US$56 million in Series B financing.
This round of financing was jointly led by Qiming Venture Capital and Yuanyi Investment.
Honghui Capital and Innovation Works followed the investment, and the old shareholder Trust Capital With continued blessing, Haoyue Capital served as the exclusive financial advisor for this round of financing
.

This round of investment will provide strong support for Herqirui's upcoming MRCT international phase II clinical research and product line construction

Herqirui is a science-driven innovative drug research and development company dedicated to source innovation.
Its China headquarters is located in Nanjing, and it also has research and development bases and offices in Shanghai and Beijing
.

The company was founded by Professor Xiao Ruiping, the dean of the School of Future Technology of Peking University and the associate editor of the New England Journal of Medicine

Focusing on the three major areas of women's health, endocrinology and cardiovascular diseases, Heqirui has further established a diversified R&D pipeline through independent research and development and a license-in dual-drive model for the current unmet clinical needs
.

Previously, Qirui and Bayer AG signed a global exclusive license agreement for the development and industrialization of monoclonal antibodies targeting the prolactin (PRL) receptor
.

Potential indications for this antibody include male and female pattern alopecia, endometriosis, and other chronic diseases

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

[First issue] Heqirui Medicine, dedicated to source innovation, successfully completed US$56 million in Series B financing to accelerate the creation of a global innovative R&D platform

05-22

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Heqirui Medicine completes US$56 million in Series B financing

Related Articles

[First issue] Heqirui Medicine, dedicated to source innovation, successfully completed US$56 million in Series B financing to accelerate the creation of a global innovative R&D platform